Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lawrence

Showing results (471-480 of 534) with videos related to

Pageof 54
Sort By:
Science Advances|June 24, 2021
Rejection of benign melanocytic nevi by nevus-resident CD4<sup>+</sup> T cellsErik B Schiferle, Se Yun Cheon, Seokjin Ham, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Nature|August 9, 2013
Nitrogen losses in anoxic marine sediments driven by Thioploca-anammox bacterial consortiaM G Prokopenko, M B Hirst, L De Brabandere, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 23, 2022
Identification of fusions with potential clinical significance in melanomaJakob M T Moran, Long P Le, Valentina Nardi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2021
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort StudyGirish S Naik, Elizabeth I Buchbinder, Justine V Cohen, et al.
The Oncologist|October 12, 2020
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient SettingSienna M Durbin, Leyre Zubiri, Andrzej Niemierko, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
International Journal of Radiation Oncology, Biology, Physics|March 28, 2025
Temporal Apparent Diffusion Coefficient Changes During Chemoradiation: An Imaging Biomarker for Tumor Response Monitoring and Spatial Recurrence Prediction in GlioblastomaDaniel Moore-Palhares, Liam S P Lawrence, Sten Myrehaug, et al.
The Oncologist|February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic ControlChristopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.
Pageof 54

Showing results (471-480 of 534) with videos related to

Sort By:
Pageof 54
Science Advances|June 24, 2021
Rejection of benign melanocytic nevi by nevus-resident CD4<sup>+</sup> T cellsErik B Schiferle, Se Yun Cheon, Seokjin Ham, et al.
Cancer|March 1, 2014
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitorsAllison Ackerman, Oliver Klein, David F McDermott, et al.
Nature|August 9, 2013
Nitrogen losses in anoxic marine sediments driven by Thioploca-anammox bacterial consortiaM G Prokopenko, M B Hirst, L De Brabandere, et al.
Melanoma Research|September 14, 2018
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanomaShalin Shah, Jason J Luke, Heather A Jacene, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 23, 2022
Identification of fusions with potential clinical significance in melanomaJakob M T Moran, Long P Le, Valentina Nardi, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2021
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort StudyGirish S Naik, Elizabeth I Buchbinder, Justine V Cohen, et al.
The Oncologist|October 12, 2020
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient SettingSienna M Durbin, Leyre Zubiri, Andrzej Niemierko, et al.
Journal of the American Academy of Dermatology|February 22, 2022
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanomaMaria S Asdourian, Tracey S Otto, Ted V Jacoby, et al.
International Journal of Radiation Oncology, Biology, Physics|March 28, 2025
Temporal Apparent Diffusion Coefficient Changes During Chemoradiation: An Imaging Biomarker for Tumor Response Monitoring and Spatial Recurrence Prediction in GlioblastomaDaniel Moore-Palhares, Liam S P Lawrence, Sten Myrehaug, et al.
The Oncologist|February 24, 2019
Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic ControlChristopher Alvarez-Breckenridge, Anita Giobbie-Hurder, Corey M Gill, et al.
Pageof 54